Novartis Pharmaceuticals Corp.
Date Sent
File
Warning Letter to Novartis Pharmaceuticals Corp.
(175.19 KB)
Displaying 21 - 40 of 346
Concurring Statement of Commissioner Andrew N. Ferguson Joined by Commissioner Melissa Holyoak Regarding the Second Pharmacy Benefit Managers Interim Staff Report
Date
By
Andrew N. Ferguson, Chairman;
Melissa Holyoak, Former Commissioner
Matter Number
P221200
FTC Releases Second Interim Staff Report on Prescription Drug Middlemen
Date
The Federal Trade Commission today published a second interim staff report on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ (PBMs) influence over specialty...
FTC Announces Tentative Agenda for January 14 Open Commission Meeting
Date
Today, Federal Trade Commission Chair Lina M. Khan announced that an open meeting of the Commission will be held virtually on Tuesday, January 14, 2025. The open meeting will commence at 11 a.m. ET...
FTC Statement on Appellate Court Decision Ordering Delisting of Teva Inhaler Patents
Date
Today, the U.S. Court of Appeals for the Federal Circuit affirmed a lower district court order against pharmaceutical maker Teva requiring the drugmaker to delist several asthma inhaler patents from...
FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices
Date
Today, the Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group...
FTC Seeks Public Comments on Cooperativa De Farmacias Puertorriqueñas Request to Modify Final Commission Order
Date
The Federal Trade Commission is seeking public comment on a petition by a Puerto Rican cooperative of independent pharmacy owners, Cooperativa De Farmacias Puertorriqueñas, also known as Coopharma...
FTC Submits Comment Supporting Proposed FDA Guidance on Interchangeable Biosimilar Drugs
Date
The Federal Trade Commission submitted a comment supporting the Food and Drug Administration’s (FDA) draft guidance regarding interchangeable biosimilar drugs that can be substituted for brand-name...
FTC Submits Comment Supporting Proposed USPTO Terminal Disclaimer Rule
Date
The Federal Trade Commission submitted a comment supporting a proposed U.S. Patent and Trademark Office (USPTO) rule regarding new requirements associated with patent terminal disclaimer practice to...
Statement of Chair Lina M. Khan Joined by Commissioners Alvaro M. Bedoya & Rebecca Kelly Slaughter Regarding the Pharmacy Benefit Managers Interim Staff Report
Date
By
Lina M. Khan, Former Chair and Commissioner;
Alvaro Bedoya, Former Commissioner;
Rebecca Kelly Slaughter, Former Commissioner
FTC Releases Interim Staff Report on Prescription Drug Middlemen
Date
The Federal Trade Commission today published an interim report on the prescription drug middleman industry that underscores the impact pharmacy benefit managers (PBMs) have on the accessibility and...
FTC Submits Comment Supporting Proposed USPTO Rule
Date
The Federal Trade Commission today submitted a comment supporting a proposed U.S. Patent and Trademark Office (USPTO) rule involving the disclosure of patent settlement agreements. In April, the USPTO...
FTC Expands Patent Listing Challenges, Targeting More Than 300 Junk Listings for Diabetes, Weight Loss, Asthma and COPD Drugs
Date
Today, the Federal Trade Commission expanded its campaign against pharmaceutical manufacturers’ improper or inaccurate listing of patents in the Food and Drug Administration’s (FDA) Orange Book...
Displaying 21 - 40 of 346